131 filings
Page 6 of 7
8-K
ww33zu bgy38htq
21 Sep 15
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
b7nzc21qvoxwtz1uyuab
16 Sep 15
Other Events
12:00am
8-K
hrx7h1bgc1ews
2 Sep 15
Intra-cellular Therapies Announces Publication of Positive Phase 2 Schizophrenia Study In the Journalbiological Psychiatry
12:00am
8-K
lm0r2k eznviqv80
5 Aug 15
Intra-Cellular Therapies Reports Second Quarter 2015 Financial Results and Provides Corporate Update
12:00am
8-K
g1wpdujxlbd9vade
22 Jul 15
Other Events
12:00am
8-K
n31 3jcd31hy34ti8
24 Jun 15
Intra-Cellular Therapies Reports Initiation of Randomization for ITI-007-302 Phase 3 Trial in Schizophrenia
12:00am
8-K
0xpohw9m6bnimn22c7
18 Jun 15
Departure of Directors or Certain Officers
12:00am
8-K
nr1rh0dwc8oheht84zew
15 Jun 15
Other Events
12:00am
8-K
nb8wfi8yln x6oc
28 May 15
Entry into a Material Definitive Agreement
12:00am
8-K
wzjr52us
19 May 15
Other Events
12:00am
8-K
qgqux
30 Apr 15
Intra-Cellular Therapies Reports First Quarter 2015 Financial Results and Provides
12:00am
8-K
zlb9vo y8
31 Mar 15
Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research
12:00am
8-K
ytey43haal0tuf kv0
12 Mar 15
Intra-Cellular Therapies Announces Closing of $130 Million Public Offering Including
12:00am
8-K
gfm24
6 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
slbt3 syry5vtq
4 Mar 15
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
mye0xkzhba
3 Nov 14
Results of Operations and Financial Condition
12:00am
8-K
xehh16u
12 Aug 14
Company announces successful End-of Phase 2 meeting with the FDA and Phase 3 plans for ITI-007 for schizophrenia
12:00am
8-K
fskn s8hnmf09s21g06k
3 Jul 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
9wgmep1eygptc35
6 May 14
Other Events
12:00am
8-K
p8i 4863zii7ru
5 May 14
Intra-Cellular Therapies Reports First Quarter 2014 Financial Results
12:00am